Catheter-based closure of residual leaks after percutaneous occlusion of the left atrial appendage
Introduction The purpose of this study was to evaluate safety and efficacy of catheter‐based occlusion of residual leaks after percutaneous closure of the left atrial appendage (LAA). Methods All cases of LAA closure at our center were reviewed to identify secondary interventions for residual leaks....
Saved in:
Published in | Catheterization and cardiovascular interventions Vol. 87; no. 7; pp. 1324 - 1330 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Blackwell Publishing Ltd
01.06.2016
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Introduction
The purpose of this study was to evaluate safety and efficacy of catheter‐based occlusion of residual leaks after percutaneous closure of the left atrial appendage (LAA).
Methods
All cases of LAA closure at our center were reviewed to identify secondary interventions for residual leaks. Leaks with a width of more than 3 mm by transesophageal echocardiography (TEE) were considered relevant. In a case‐specific approach, depending on the respective morphology of the defect, either an LAA occlusion device or an Amplatzer Vascular Plug was implanted under TEE and fluoroscopic guidance.
Results
Between June 2003 and December 2013, 12 patients underwent residual leak closure. All procedures were technically successful and without complications. In 10 cases (83%), complete sealing was confirmed at TEE follow‐up. In 2 patients, minimal gaps (2–3 mm) persisted and anticoagulation was continued. None of the patients had strokes during the follow‐up period.
Conclusion
Percutaneous residual leak closure after attempted LAA occlusion can be done safely and with high procedural success rates. © 2015 Wiley Periodicals, Inc. |
---|---|
Bibliography: | ark:/67375/WNG-7FQZPSBD-B istex:46EA6AF2BD5A60B73CB34333E87583CAD8CA3311 ArticleID:CCD26318 Conflict of interest? The authors’ institution has ownership interest in or has received consulting fees, travel expenses or study honoraries from the following companies: Abbott, Access Closure, AGA, Angiomed, Arstasis, Atritech, Atrium, Avinger, Bard, Boston Scientific, Bridgepoint, Cardiac Dimensions, CardioKinetix, CardioMEMS, Coherex, Contego, CSI, EndoCross, EndoTex, Epitek, Evalve, ev3, FlowCardia, Gore, Guidant, Guided Delivery Systems, Inc., InSeal Medical, Lumen Biomedical, HLT, Kensey Nash, Kyoto Medical, Lifetech, Lutonix, Medinol, Medtronic, NDC, NMT, OAS, Occlutech, Osprey, Ovalis, Pathway, PendraCare, Percardia, pfm Medical, Rox Medical, Sadra, SJM, Sorin, Spectranetics, SquareOne, Trireme, Trivascular, Velocimed, Veryan. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1522-1946 1522-726X |
DOI: | 10.1002/ccd.26318 |